Sabrina Lara Abonizio Magdalena

Sabrina Lara Abonizio Magdalena

Auto-generated profile, based on publicly available information

Sabrina Lara Abonizio Magdalena

Faculdade de Medicina de Jundiai

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 September 2024 in American Journal of Obstetrics and Gynecology
Verified
Journal Article
Closed access
HPHenrique Provinciatto
Henrique Provinciatto
YDYasmin Jardim Meirelles Dias
Yasmin Jardim Meirelles Dias
SMSabrina Lara Abonizio Magdalena
Sabrina Lara Abonizio Magdalena
MMMarcus Vinicius Barbosa Moreira
Marcus Vinicius Barbosa Moreira
LFLucas Rezende de Freitas
Lucas Rezende de Freitas
Edward Araujo JúniorEdward Araujo Júnior
Edward Araujo Júnior

26 September 2025 in Climacteric
Verified
Journal Article
Closed access
IPIsabella Melo Pompei
Isabella Melo Pompei
SMSabrina Lara Abonizio Magdalena
Sabrina Lara Abonizio Magdalena
VAVivien Suemi Arimura
Vivien Suemi Arimura
RMRogério Bonassi Machado
Rogério Bonassi Machado
CFCésar Eduardo Fernandes
César Eduardo Fernandes
LPLuciano Melo Pompei
Luciano Melo Pompei
Menopausal hormone therapy (MHT) is the most effective treatment for relieving menopausal symptoms. However, many women avoid this therapy due to fear, and in Brazil numerous cities lack access to this treatment in the public health system. This study aimed to investigate prescribing habits regarding MHT among gynecologist-obstetricians in the Brazilian public versus private health systems, and to identify the main barriers to its use. This descriptive cross-sectional study utilized a quantitative approach. Gynecologist-obstetricians from across Brazil were invited to complete a structured electronic questionnaire assessing their prescribing practices in both the public and private health sectors. A total of 433 valid responses were analyzed. Among them, 51.5% of participants reported providing care to climacteric patients in the public health system, with 46.2% working in both sectors. Among physicians practicing in both settings, 76.5% reported prescribing MHT more frequently in the private sector. The main barriers to MHT prescription in the public system were treatment cost (68.2%) and lack of availability of free medication (61.4%), while in the private system the predominant barriers were fear of therapy-related risks (93.6%), especially cancer. Only 27.8% reported free access to MHT in their cities. The findings indicate that MHT prescribing practices in Brazil are still significantly influenced by structural barriers in the public sector and by negative perceptions in the private sector. Interventions aimed at expanding access and educating both physicians and patients are essential to ensure safe and equitable use of MHT.